Finoriq research workspace
ABVC BIOPHARMA, INC. (ABVC) Historical Metrics
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices. Review ABVC valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
- Company
- ABVC BIOPHARMA, INC. (ABVC)
- Ticker
- ABVC
- Market Cap
- $32.5M
- Latest Price
- $1.2499
- Industry
- Biotech & Pharma
ABVC BIOPHARMA, INC. (ABVC) Current Valuation Metrics
Static valuation preview for ABVC BIOPHARMA, INC. (ABVC). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 128x | Revenue | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | -22.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 3.52x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.